Skip to content
value.today

Antios Therapeutics Inc.

🇺🇸 Atlanta, Georgia, USABiotechnologyFounded 2018
Total raised
$126 M
4 rounds on record
Latest round
$75 M
Nov 2021
First round on record
Nov 2018
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Antios Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2021$75 MNo. 4$50 to $250 million

Antios Therapeutics Inc.: Raise no. 4, Nov 2021

Investors in this round

35 investors had bought by the notice of Nov 16, 2021: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$75 M of $86 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Mayers · Executive Officer
  • Gregory Mayes · Executive Officer, Director
  • Tamra Adams · Executive Officer
  • Abel De La Rosa · Director
  • Benjamin Rovinski · Director
  • Craig Gordon · Director
  • Iyona Rajkomar · Director
  • Patrick Higgins · Director
  • Scott Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gregory Mayes, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 16, 2021. Read the notice at the SEC.

equitySEC
Apr 2021$32 MNo. 3$10 to $50 million

Antios Therapeutics Inc.: Raise no. 3, Apr 2021

Investors in this round

29 investors had bought by the notice of Apr 19, 2021: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$32 M of $100 M offered; $68 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Mayers · Executive Officer
  • Gregory Mayes · Executive Officer, Director
  • Tamra Adams · Executive Officer
  • Abel De La Rosa · Director
  • Benjamin Rovinski · Director
  • David Canner · Director
  • Iyona Rajkomar · Director
  • Patrick Higgins · Director
  • Scott Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”

Signed by Gregory Mayes, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 19, 2021. Read the notice at the SEC.

equitySEC
Jul 2020$4 MNo. 2$2 to $10 million

Antios Therapeutics Inc.: Raise no. 2, Jul 2020

Investors in this round

9 investors had bought by the notice of Aug 17, 2020: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abel De La Rosa · Executive Officer, Director
  • Douglas Lin Mayers · Executive Officer
  • Idean Marvasty · Executive Officer
  • Benjamin Rovinski · Director
  • Henry Lin Chen · Director
  • Nicole Vitullo · Director
  • Scott Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.”

Signed by Idean Marvasty, SVP, Finance and Strategy. Source: SEC Form D, newest notice filed Aug 17, 2020. Read the notice at the SEC.

equitySEC
Nov 2018$15 MNo. 1$10 to $50 million

Antios Therapeutics Inc.: Raise no. 1, Nov 2018

Investors in this round

10 investors had bought by the notice of Dec 5, 2018: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $25 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abel De La Rosa · Executive Officer, Director
  • Douglas Lin Mayers · Executive Officer
  • Idean Marvasty · Executive Officer
  • Benjamin Rovinski · Director
  • Henry Lin Chen · Director
  • Nicole Vitulio · Director
  • Scott Morenstein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Idean Marvasty, Senior Vice President, Finance and Strategy. Source: SEC Form D, newest notice filed Dec 5, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Antios Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2021).

    SEC Form D · Nov 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2021

That is all the official record says: Antios Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Antios Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 35 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Antios Therapeutics Inc.
NameRoleNamed in
Douglas MayersExecutive officerNov 2021
Gregory MayesExecutive officerNov 2021
Tamra AdamsExecutive officerNov 2021
Abel De La RosaExecutive officerAug 2020
Douglas Lin MayersExecutive officerAug 2020
Idean MarvastyExecutive officerAug 2020
Abel De La RosaDirectorNov 2021
Benjamin RovinskiDirectorNov 2021
Craig GordonDirectorNov 2021
Gregory MayesDirectorNov 2021
Iyona RajkomarDirectorNov 2021
Patrick HigginsDirectorNov 2021
Scott MorensteinDirectorNov 2021
David CannerDirectorApr 2021
Henry Lin ChenDirectorAug 2020
Nicole VitulloDirectorAug 2020
Nicole VitulioDirectorDec 2018